Welcome to our dedicated page for Asensus Surgical news (Ticker: ASXC), a resource for investors and traders seeking the latest updates and insights on Asensus Surgical stock.
Asensus Surgical, Inc. (NYSE American: ASXC) is a trailblazing medical device company that enhances minimally invasive surgery through digital laparoscopy. The company's flagship product, the Senhance® Surgical System, is the first machine vision system used in robotic surgery. It leverages augmented intelligence, connectivity, and robotics to address clinical, cognitive, and economic challenges in surgery.
Headquartered in Research Triangle Park, North Carolina, Asensus Surgical focuses exclusively on the research, development, and sale of medical device robotics aimed at improving surgical outcomes. The company's cutting-edge technology includes the Intelligent Surgical Unit™ that brings augmented intelligence into the operating room. One of its latest innovations is the LUNA™ Surgical System, a next-generation robotic and instrument system under development.
Committed to global healthcare improvements, Asensus Surgical has expanded its reach with the Senhance System now available in the US, EU, Japan, Russia, and select other countries. The system has recently been adopted by Nagoya University Hospital in Japan, dedicated to pediatric procedures. This marks a significant milestone, as the Senhance System offers specialized instrumentation and advanced clinical intelligence, aimed at reducing invasiveness and increasing precision in pediatric surgery.
In a recent strategic move, Asensus Surgical entered into a definitive merger agreement with KARL STORZ Endoscopy-America, Inc., a subsidiary of KARL STORZ SE & Co. KG. This merger, valued at $0.35 per share, is anticipated to enhance KARL STORZ's portfolio and market presence, particularly in the robotic surgical market. The transaction has been unanimously approved by Asensus’ Board of Directors and is expected to close during the third quarter of 2024.
Asensus Surgical continues to be driven by collaboration and human ingenuity, striving to make surgery more accessible and predictable while delivering consistently superior outcomes. For more detailed information, visit www.asensus.com.
Asensus Surgical, Inc. (NYSE American: ASXC) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 12:00 PM PST. This event aims to showcase the company's innovative approach to Performance-Guided Surgery, utilizing advanced technology to improve surgical outcomes. The presentation will be accessible via a live audio webcast on the company's investor page, with replays available for 30 days. Asensus Surgical focuses on enhancing surgeon control and reducing variability using the Senhance Surgical System.
Asensus Surgical (NYSE American: ASXC) announced the installation of a second Senhance Surgical System at Kitakyushu General Hospital in Japan, marking a significant expansion of its surgical offerings. Kitakyushu has successfully utilized its first system since January 2020, completing over 300 procedures. The addition of this second system highlights the clinical value and versatility of the Senhance platform, which incorporates augmented intelligence and advanced features like haptic feedback and the Intelligent Surgical Unit. This development is expected to enhance patient outcomes and further solidify Asensus's position in the digital surgery market.
Asensus Surgical (NYSE American: ASXC) has signed an agreement with Kashiwa Kosei General Hospital in Japan to lease the Senhance® Surgical System. This partnership is part of Asensus's expansion in a rapidly growing market. The Senhance system, known for its digital laparoscopic capabilities and use of augmented intelligence, aims to enhance surgical performance and patient outcomes. With a new thoracic indication approved, the hospital's surgery department is set to benefit from advanced technology, improving patient care and surgical effectiveness.
Asensus Surgical, Inc. (ASXC) announces that GPR Gesundheits- und Pflegezentrum Klinikum in Rüsselsheim, Germany, will lease its Senhance Surgical System. This marks the 10th hospital in Germany to adopt this technology, known for enhancing surgical performance through augmented intelligence and machine learning. The system is designed for high-volume procedures in specialties such as gynecology and urology. The partnership highlights increasing traction in Germany, Europe's largest robotics market, which could positively influence surgical demand and outcomes.
Asensus Surgical, Inc. (ASXC) has announced the sale of a Senhance Surgical System to a distribution partner in Germany. This system will be installed at an oncology-focused hospital, showcasing an increasing demand for the technology in Eastern Europe and the CIS region. The CEO, Anthony Fernando, expressed enthusiasm over the hospital's financial commitment to the Senhance System, emphasizing its clinical relevance and potential to improve surgical outcomes. The Senhance System is designed to enhance surgical precision and efficiency through augmented intelligence and machine learning.
Asensus Surgical, Inc. (NYSE American: ASXC) announced that CFO Shameze Rampertab will participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference in Miami on December 8, 2022. The company will present a panel discussion on early commercial MedTech technologies at 11:00 AM ET, followed by a Key Opinion Leader Luncheon at 12:15 PM ET, featuring Dr. Steven McCarus. Asensus is focused on enhancing surgical outcomes through Performance-Guided Surgery™ and the Senhance® Surgical System, which is currently available in multiple regions.
Asensus Surgical, Inc. (ASXC) reported its third quarter 2022 results, maintaining revenue at $2.6 million year-over-year, driven by over 1,900 procedures performed, a 27% increase from 2021. The company initiated five new Senhance programs and submitted a 510(k) application for pediatric use in the U.S. Operating expenses rose to $17.2 million, leading to a net loss of $18.9 million or $0.08 per share. The firm held $88.3 million in cash and investments as of September 30, 2022, and anticipates initiating 8-10 new Senhance systems in 2022.
Asensus Surgical (ASXC) has announced that Dr. von Hauner Children’s Hospital in Munich, Germany, has signed an agreement to lease the Senhance Surgical System, marking the first dedicated pediatric use of the system. This represents a significant milestone as the 9th hospital in Germany to adopt the Senhance technology, aimed at improving pediatric surgical outcomes through minimally invasive techniques. The system's advanced features, including 3mm instruments and haptic feedback, are expected to enhance the surgical experience for pediatric surgeons and their patients.
Asensus Surgical, Inc. (NYSE American: ASXC) announced plans to release its third-quarter financial and operational results for 2022 after market hours on November 10, 2022. A conference call will occur at 4:30 p.m. ET on the same day to discuss these results, with a simultaneous webcast available. Asensus focuses on transforming surgical practices through its Senhance Surgical System, aiming for superior outcomes in Performance-Guided Surgery. Their technology integrates machine vision and deep learning to address current shortcomings in surgical procedures.
Asensus Surgical, Inc. (ASXC) announced a leasing agreement for its Senhance Surgical System with the St. Bernhard Hospital in Germany. This advanced robotic platform focuses on minimally invasive surgery and is equipped with augmented intelligence to enhance surgical performance and patient outcomes. The system features unique capabilities like haptic feedback and 3D visualization, making it a pioneering addition to the clinic's surgical offerings. The partnership aims to improve surgical precision and reduce variability.
FAQ
What is the current stock price of Asensus Surgical (ASXC)?
What is the market cap of Asensus Surgical (ASXC)?
What does Asensus Surgical, Inc. do?
Where is Asensus Surgical headquartered?
What is the Senhance® Surgical System?
What is the latest innovation from Asensus Surgical?
In which regions is the Senhance® Surgical System available?
Has Asensus Surgical recently partnered with any hospitals?
What is the merger agreement with KARL STORZ about?
When is the merger with KARL STORZ expected to close?
Will Asensus Surgical continue to be publicly traded after the merger?